Research and Markets: Gain an Insight into the Latest Mergers and Acquisitions Undertaken By Therakos the Medical Devices Company
Posted on: Friday, 12 January 2007, 12:01 CST
Research and Markets (http://www.researchandmarkets.com/reports/c48341) has announced the addition of the Espicom Business Intelligence Ltd report: Therakos Medical Device Company Intelligence Report to their offering.
Medical Device Company Intelligence Reports provide a full review of the company's activities, from its origins to its latest corporate activity, including mergers and acquisitions, agreements, divestitures, major purchasing contracts and litigation. Sections are included on products, international activities and R&D, as well as a full, in-depth five year financial analysis. An introduction to each report and a full table of contents is provided for review. More than 60 Medical Device Company Intelligence Reports are currently available.
Topics Covered
EXECUTIVE SUMMARY
OVERVIEW
PRODUCT PORTFOLIO AND R&D
UVAR XTS SYSTEM
UVAR XTS Fluid Logic Controller
UVADEX (Methoxsalen)
RESEARCH AND DEVELOPMENT
Research Projects
Photopheresis with UVADEX to Treat Acute Graft-versus-Host Disease
Reduced Intensity Transplant Using Extracorporeal Photopheresis
Extracorporeal Photochemotherapy in Patients with HIV
Photopheresis as a Treatment of CTCL (Stage 1A, 1B, 2A)
INTERNATIONAL ACTIVITIES
APPENDICES
APPENDIX 1 - KEY CORPORATE EVENTS
Summary
Headquartered in Exton, Pennsylvania, USA, Therakos is a Johnson & Johnson company which was established in order to foster advances in the extracorporeal management of disease. The company has undertaken extensive research into photoimmune therapy which led to the development of photopheresis, also known as extracorporeal photoimmune therapy, an approach to the management of disease using photoactivatable agents and light.
The company's principal product, the UVAR XTS Photopheresis System, is an integrated device for photopheresis and is approved by the FDA and in many other countries around the world for the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma.
Therakos is also conducting clinical trials with the aim of seeking FDA approval for a number of new disease indications for photopheresis, including emerging indications in the field of immune-mediated inflammatory diseases and disorders such as the prevention and treatment of graft-versus-host disease.
Therakos works closely with other J&J companies in the development of photopheresis, including Cordis, Janssen Italy, Johnson & Johnson Medical France, Johnson & Johnson Medical Germany and Johnson & Johnson Medical UK.
For more information visit http://www.researchandmarkets.com/reports/c48341
Source: Business Wire
Related Articles
- On the Trail of a Vaccine for Lyme Disease: Yale Researchers Target Tick Saliva
- Johnson City Medical Center Saves $550,000 with Smart Square(R)
- Republic of Korea Multiparameter Patient Monitoring Devices Market Report
- Research and Markets: This Report on Covidien Ltd. Tyco Healthcare Medical Equipment Company is Now Available
- U.S. Breast Disease Diagnostic and Therapeutic Devices Market Poised to Grow to Over $2.7 Billion By 2012
- Aethlon Medical Signs Cooperative Research and Development Agreement With The U.S. Army Medical Research Institute of Infectious Diseases
- MontaVista Accelerates Growth and Continues Market Leadership in Linux Solutions for Intelligent Devices and Communications Infrastructure
- Healthcare Daily Data Bytes 2006 - an Indispensable CD-ROM for Researching New Projects, Writing Reports and Compiling Presentations
- WomenHeart and the Society for Women's Health Research Unveil the 10 Q Report, a Groundbreaking Research Agenda to Fight Heart Disease in Women
- Medivir: Advances in Chronic Obstructive Pulmonary Disease (COPD) Research Program
 |
 |
User Comments (0)
RSS Feeds